Improve Human Health to Make Life More Dignified

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris Appoints Dr. Linda Wu as Chief Development Officer

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

January 17, 2023

Asieris Appoints Dr. Linda Wu as Chief Development Officer

December 12, 2022

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

December 12, 2022

Asieris’Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

December 3, 2022

The First IBCC Unveiled in Hainan

November 14, 2022

Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”

November 11, 2022

The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study

Technology Platform